Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?

Shares of Exelixis, Inc. (EXEL) have risen 20.7% in the past three months compared with the industry's growth of 6.3%. The stock has also outperformed the sector and the S&P 500 Index. Exelixis has been a consistent outperformer in the year so far on the back of the strong performance of its lead drug Cabometyx and encouraging pipeline progress. EXEL Outperforms Industry, Sector & S&P 500 Image Source: Zacks Investment Research Cabometyx Boosts EXEL Cabometyx maintained its status as the leading tyrosine ki ...